skip to main content

H.R. 2430: FDA Reauthorization Act of 2017

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

The bill’s titles are written by its sponsor.

The federal budget process occurs in two stages: appropriations, which set overall spending limits by agency or program, and authorizations, which direct how federal funds should (or should not) be used. Appropriation and authorization provisions are typically made for single fiscal years. A reauthorization bill like this one renews the authorizations of an expiring law.

What you can do

Overview

Introduced:

May 16, 2017

Status:

Passed House & Senate (President next) on Aug 3, 2017

This bill was passed by Congress on August 3, 2017 and goes to the President next.

Sponsor:

Greg Walden

Representative for Oregon's 2nd congressional district

Republican

Text:

Read Text »
Last Updated: Aug 5, 2017
Length: 86 pages

Prognosis:

94% chance of being enacted according to Skopos Labs (details)

History

May 16, 2017
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

May 18, 2017
 
Considered by Health

A committee held a hearing or business meeting about the bill.

Jun 7, 2017
 
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Jun 7, 2017
 
Considered by House Committee on Energy and Commerce

A committee held a hearing or business meeting about the bill.

Jul 10, 2017
 
On House Schedule

The House indicated that this bill would be considered in the week ahead.

Jul 11, 2017
 
Reported by House Committee on Energy and Commerce

A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions.

Jul 12, 2017
 
Passed House (Senate next)

The bill was passed in a vote in the House. It goes to the Senate next. The vote was by voice vote so no record of individual votes was made.

Aug 3, 2017
 
Passed Senate

The bill was passed by both chambers in identical form. It goes to the President next who may sign or veto the bill.

Pending
 
Signed by the President

H.R. 2430 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 2430 — 115th Congress: FDA Reauthorization Act of 2017.” www.GovTrack.us. 2017. August 18, 2017 <https://www.govtrack.us/congress/bills/115/hr2430>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.